Global  

“News neutrality by unbiased coverage”
One News Page
> >

Non-Small Cell Lung Cancer - United States Market and Competitive Landscape (2018-2023) - ResearchAndMarkets.com

Business Wire Thursday, 11 October 2018
Non-Small Cell Lung Cancer - United States Market and Competitive Landscape (2018-2023) - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering This report provides comprehensive insights into Non-Small Cell Lung Cancer pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares. The study accurately estimates and forecast Non-Small Cell Lung Cancer market size and drug sales. This research also provides insights into Non-Small
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors

PLEASANTON, Calif., HANGZHOU, China and ANN ARBOR, Mich., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT), Inc., a U.S. and China-based innovative...
GlobeNewswire - Press Releases

Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints

Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints
SUZHOU, China, Dec. 13, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class China-based biopharmaceutical company that develops...
PR Newswire Asia - Press Releases

Genprex boosts outreach to investors with planned launch of corporate website

Gene-therapy company Genprex Inc (NASDAQ:GNPX) is boosting its outreach efforts to investors with the launch of a corporate website in 2019 and new email alerts....
Proactive Investors - Business

FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

· *Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous...
GlobeNewswire - Press Releases


Tweets about this


Other recent news in Press Releases

Vantagepoint ai Trading SOFTWARE Expands Global Partnership to ItalySaudi Arabia $179 MILLION Oil & Gas Drilling Tools Market, Competition Forecast & Opportunities, 2023
Online Retailer BuyBest Celebrates the CHRISTMAS Season With a Super Sale December 17th through December 25thBragar Eagel & Squire, P.C. is Investigating JOHNSON & JOHNSON (JNJ) on Behalf of Stockholders and Encourages JNJ Investors to Contact the Firm
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest